<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Controlling autoimmunity in sporadic inclusion-body myositis</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>MD</roleName><forename type="first">Lawrence</forename><surname>Steinman</surname></persName>
							<email>steinman@stanford.edu</email>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Neurology and Neurological Sciences</orgName>
								<orgName type="department" key="dep2">Beckman Center for Molecular Medicine</orgName>
								<orgName type="institution">Stanford University</orgName>
								<address>
									<settlement>Stanford</settlement>
									<region>CA</region>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Neurology and Neurological Sciences</orgName>
								<orgName type="department" key="dep2">Beckman Center for Molecular Medicine</orgName>
								<orgName type="institution">Stanford University</orgName>
								<address>
									<postCode>94305</postCode>
									<settlement>Stanford</settlement>
									<region>CA</region>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Controlling autoimmunity in sporadic inclusion-body myositis</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">26DC3E02C768B3B46777F454769AD50F</idno>
					<note type="submission">Received June 22, 2005. Accepted in final form October 14, 2005.</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2" ident="GROBID" when="2023-03-30T18:13+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Sporadic inclusion-body myositis (s-IBM) spans two areas of interest in my research lab, the role of protein aggregation in neurodegenerative disease <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref> and the role of secondary autoimmunity in degenerative conditions in the nervous system 5-10 and in muscle. <ref type="bibr" target="#b10">11,</ref><ref type="bibr" target="#b11">12</ref> After some comments on the potential pathologic role of inclusion bodies themselves, I shall focus attention on two approaches to controlling the autoimmune response in muscle tissue: inhibition of lymphocyte homing with antibodies to alpha 4 beta 1 integrin, <ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref> and nonspecific downregulation of autoimmunity with statins. <ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref> Aggregations in neurodegenerative disease. We have studied the role of transglutaminase in the crosslinking of huntingtin aggregates in Huntington disease (HD). <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref> The aggregates in HD have characteristics of covalently linked protein multimers, with occasional ordered areas of amyloid with its accompanying birefrigent optical properties when stained with Congo red. In HD we can ameliorate the disease modestly by inhibiting the enzyme transglutaminase, TGase. TGase catalyzes the formation of glutaminyl-lysyl linkages. Inhibtion of TGase in vivo prolonged lifespan, and diminished tremor and weight loss in a transgenic animal model of HD. Despite the fact that TGase is part of the aggregate in HD, and that TGase inhibition ameliorates disease in the transgenic animal model of HD, treatment with cystamine does not appreciably reverse gross aggregates, unless instituted at a very early stage of disease. Increasing evidence suggests that whereas early microaggregates may have pathologic properties, gross aggregates may not be pathogenic per se, and might even have protective characteristics. <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref> Strategies aimed at blocking aggregates could certainly be given together with treatments that block the accumulation of inflammatory cells in muscle.</p><p>Treating the inflammatory/autoimmune features of s-IBM. The inflammatory response in muscle in s-IBM has many features of an autoim-</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>mune infiltrate, replete with CD4 and CD8 T cells and macrophages. <ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref> The milieu in muscle provides all the necessary features for involvement of both the innate and adaptive arms of the immune response. It is interesting to note that even degenerative diseases of muscle, like Duchenne's muscular dystrophy, have aspects of the adaptive immune response with T cell infiltration and macrophages. Using PCR to monitor T-cell receptor rearrangements in pathologic tissue specimens, we have been able to see clonal rearrangments of T-cell receptor V-D-J segments in polymyositis and Duchenne's muscular dystrophy. The nature of the T-cell receptor rearrangments in Duchenne muscle has aspects of an antigen specific immune response, reminiscent of what is observed in polymyositis. <ref type="bibr" target="#b10">11,</ref><ref type="bibr" target="#b11">12</ref> At this time, however, we do not know the targets of the adaptive immune response in s-IBM, so antigen specific approaches to tolerizing these aberrant responses is not possible. <ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref> Even when we do know the targets of the adaptive immune response, including the detailed specificity of T cells and antibodies in autoimmune diseases, ranging from myasthenia gravis to MS, we are woefully inept at shutting down adaptive immunity in an antigen-specific manner, and inducing specific tolerance. <ref type="bibr" target="#b13">14,</ref><ref type="bibr" target="#b14">15</ref> Instead most of our success in immune therapy to date has come from intervention in innate immune pathways. <ref type="bibr" target="#b13">14,</ref><ref type="bibr" target="#b14">15</ref> Among the relevant pathways worthy for clinical trials in s-IBM would be the use of blockade of lymphocyte homing, and the application of statins to block a spectrum of pathogenic innate immune responses.</p><p>Blockade of lymphocyte homing with antibodies to alpha-4 beta-1 integrin was approved for reduction of relapses in relapsing remitting MS in November 2004. <ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref> However, the drug Tysabri, a humanized monoclonal antibody, was withdrawn in February 2005 due to three cases (as of this writing) of progressive multifocal leukoencephalopathy (PML) in patients who have received the newly approved drug. Statins are therefore much more attractive in s-IBM because of their dual virtues as cholesterol lowering drugs and because of their potent anti-inflammatory properties. <ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref> Blockade of lymphocyte homing for treatment of s-IBM. In the past 15 years, the steps involved in the homing of lymphocytes to inflamed tissue have been elucidated. Lymphocytes, flowing in the venules of the vasculature, are slowed in the vicinity of inflammation by two signals, one coming from chemokines, and the second from a variety of adhesion molecules including selectins and integrins. In 1992 we showed that alpha-4 beta-1 integrin was critical for the entry of lymphocytes into inflamed brain. <ref type="bibr" target="#b12">13,</ref><ref type="bibr" target="#b14">15</ref> Alpha-4 beta-1 integrin <ref type="bibr" target="#b12">13,</ref><ref type="bibr" target="#b14">15</ref> was subsequently shown to be the key molecule in homing to a number of sites including the intestines in inflammatory bowel disease, Crohn's disease, the brain in MS, and the joints in rheumatoid arthritis. Blockade of lymphocyte homing was accompanied by spectacular success in clinical trials for rheumatoid arthritis, Crohn's disease and MS. In a 2-year, phase III trial of a humanized antibody named Tysabri to alpha-4 beta-1 integrin for treatment of MS, the relapse rate was lowered by 66% compared to placebo, with monthly treatment at doses of 3 to 6 milligrams per kilogram body weight of the humanized monoclonal. This lead to the approval of Tysabri at the end of 2004. However, within 3 months the drug was withdrawn because of three cases (at the time of this writing) of PML, a rare infection with a polyoma virus, JC virus, typically seen in immunosuppressed patients taking medicines to suppress transplant rejection or in patients with HIV. Apparently the success in blocking lymphocyte entry into the CNS allowed the JC virus to replicate unchecked and cause this fatal infection. The notion that blockade of lymphocyte homing as a safe and effective strategy to treat inflammatory disease was proven wrong. Blockade of lymphoctye adhesion was efficacious, but the risk of a fatal infection, with three known in the first few thousand treated patients, is unacceptable. This therapeutic approach is therefore misguided: without immune surveillance the risk of opportunistic infection is simply too high.</p><p>As the tragic story of lymphocyte blockade emerges, it appears that there may be a very interesting reason why progressive multifocal leukoencephalopathy is seen, and not other typical opportunistic infections like tuberculosis or fungal infections. The polyoma viruses, including JC virus (Ousman and Steinman, unpublished observations) have receptors for integrins, <ref type="bibr" target="#b20">21</ref> and blockade of integrins, may somehow modulate the dormancy and spread of these viruses in brain. Blockade of lymphocyte homing, once considered a highly attractive therapy for treatment of S-IBM, can no longer be considered as worth the risk of a potentially life threatening opportunistic infection with JC virus, causing progressive multifocal leukoencephalopathy.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Use of statins as cholesterol lowering and antiinflammatory drugs in s-IBM.</head><p>Statins, devised as HMG-CoA reductase inhibitors to lower cholesterol, have remarkable anti-inflammatory properties. <ref type="bibr" target="#b7">8,</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref> Oral administration of 80 mg/kg simvastatin (Zocor) reduced the expected number of new gadoliniumenhancing lesions in relapsing-remitting MS patients by 44% in a small 6-month open-label trial. <ref type="bibr" target="#b21">22</ref> Atorvastatin (Lipitor) has also shown promising results in lowering disease scores and vascular risk factors in patients with rheumatoid arthritis and is currently being tested in MS in a multicenter, placebo-controlled trial. <ref type="bibr" target="#b22">23</ref> Studies in EAE and other models of autoimmune disease have revealed that statin drugs interfere with the autoimmune destruction of target tissues by inhibiting multiple arms of the immune response. <ref type="bibr" target="#b7">8,</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b23">[24]</ref><ref type="bibr" target="#b24">[25]</ref><ref type="bibr" target="#b25">[26]</ref> For instance, in EAE, lovastatin prevents the production of the inflammatory mediators tumor necrosis factor, gamma interferon and inducible nitric oxide synthase by astrocytes, microglia, and infiltrating macrophages in the CNS. <ref type="bibr" target="#b23">24</ref> Atorvastatin inhibits inducible expression of MHC class II and costimulatory molecules on CNS-resident antigen presenting cells. <ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref> Moreover, statin drugs prevent expansion and differentiation of Th1 autoreactive T cells <ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref> and the migration of these autoreactive T cells across the blood-brain barrier. <ref type="bibr" target="#b25">26</ref> All of these anti-inflammatory effects would be virtues for treatment of S-IBM.</p><p>In addition, Askanas and Engel have proposed "that within s-IBM muscle fibers, cholesterol, instead of being properly metabolized or cleared, is deposited, with caveolin-1, at sites of Abeta accumulation and possibly at sites of Abeta precursor protein processing, where it may adversely increase A beta production and induce Abeta misfolding and aggregation." <ref type="bibr" target="#b16">17</ref> Therefore, a treatment that not only has multiple virtues as an anti-inflammatory, but also lowers cholesterol would seem to have optimal specifications for use in S-IBM. The benefits and risks of statins for treatment of s-IBM are outlined in the table. </p></div><figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table</head><label></label><figDesc>Benefits and risks of statin therapy for s-IBMMechanism of actionReduction in expression of inducible MHC class II in muscleReduction in lymphocyte homing to muscle Reduction in inflammatory cytokine and NO production in muscle</figDesc><table><row><cell>Clinical benefit</cell></row><row><cell>Reduction of inflammation at multiple levels</cell></row><row><cell>Reduction in cholesterol, reduction in A beta misfolding and</cell></row><row><cell>aggregation</cell></row><row><cell>Potential side effects</cell></row><row><cell>Rhabdomyolysis</cell></row><row><cell>Hepatotoxicity</cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0">January 2006 NEUROLOGY 66(Suppl 1) S57</note>
		</body>
		<back>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Transglutaminase aggregates huntingtin into non-amyloidogenic polymers and its enzymatic activity is increased in Huntington&apos;s Disease brain nuclei</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename><surname>Karpuj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Garren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Slunt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Science U S A</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="7388" to="7393" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">N (epsilon)-(gamma-Lglutamyl)-L-lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington&apos;s disease</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Jeitner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Bogdanov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">R</forename><surname>Matson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurochem</title>
		<imprint>
			<biblScope unit="volume">79</biblScope>
			<biblScope unit="page" from="1109" to="1112" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Evidence for a role for transglutaminase in Huntington&apos;s disease and the potential therapeutic implications</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename><surname>Karpuj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Becher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Steinman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurochem Int</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="31" to="36" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Prolonged survival and decreased abnormal movements in transgenic model of Huntington&apos;s disease, with administration of cystamine, a transglutaminase inhibitor</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename><surname>Karpuj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Becher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Springer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Med</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="143" to="149" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Autoimmune disease</title>
		<author>
			<persName><forename type="first">L</forename><surname>Steinman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Scientific American</title>
		<imprint>
			<biblScope unit="volume">269</biblScope>
			<biblScope unit="page" from="106" to="114" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Multiple sclerosis: a two stage disease</title>
		<author>
			<persName><forename type="first">L</forename><surname>Steinman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Immunol</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="762" to="765" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Elaborate interactions between the immune and nervous systems</title>
		<author>
			<persName><forename type="first">L</forename><surname>Steinman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Immunol</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="575" to="581" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Diverse targets for intervention during inflammatory and neurodegenerative phases of multiple sclerosis</title>
		<author>
			<persName><forename type="first">S</forename><surname>Zamvil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Steinman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuron</title>
		<imprint>
			<biblScope unit="volume">338</biblScope>
			<biblScope unit="page" from="685" to="688" />
			<date>200</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">T cell receptor V beta gene rearrangements in the spinal cords and cerebrospinal fluid of patients with amyotrophic lateral sclerosis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Panzara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Gussoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Begovich</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurobiology of Disease</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="392" to="405" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">The cost of immune-mediated &quot;collateral damage&quot; in the nervous system</title>
		<author>
			<persName><forename type="first">L</forename><surname>Steinman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="463" to="465" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Specific T-cell receptor gene rearrangements at the site of muscle degeneration in Duchenne muscular dystrophy</title>
		<author>
			<persName><forename type="first">E</forename><surname>Gussoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">K</forename><surname>Pavlath</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Miller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">153</biblScope>
			<biblScope unit="page" from="4798" to="4805" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">TCR repertoire analysis of T lymphocytes infiltrating polymyositis muscles: restricted V␣/␤ rearrangements may indicate antigen driven selection</title>
		<author>
			<persName><forename type="first">R</forename><surname>Mantegazza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Andreetta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bernasconi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="page" from="2880" to="2886" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Prevention of experimental autoimmune encephalomyelitis by antibodies against ␣4␤1 integrin</title>
		<author>
			<persName><forename type="first">T</forename><surname>Yednock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Cannon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Fritz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Sanchez-Madrid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Steinman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Karin</forename><forename type="middle">N</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">356</biblScope>
			<biblScope unit="page" from="63" to="66" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Immune therapy for autoimmune diseases</title>
		<author>
			<persName><forename type="first">L</forename><surname>Steinman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">305</biblScope>
			<biblScope unit="page" from="212" to="216" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Design of effective immunotherapy for human autoimmunity</title>
		<author>
			<persName><forename type="first">M</forename><surname>Feldmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Steinman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">435</biblScope>
			<biblScope unit="page" from="612" to="619" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">The HMG-CoA Reductase Inhibitor, Atorvastatin, Promotes a Th2 Bias and Reverses Paralysis in CNS Autoimmune Disease</title>
		<author>
			<persName><forename type="first">S</forename><surname>Youssef</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Stuve</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Patorroyo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">420</biblScope>
			<biblScope unit="page" from="78" to="84" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Proposed pathogenic cascade of inclusion body myositis: importance of amyloid-beta, misfolded proteins, predisposing genes and aging</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="737" to="744" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Understanding the immunopathogenesis of inclusion body myositis: present and future prospects</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rev Neurol</title>
		<imprint>
			<biblScope unit="volume">158</biblScope>
			<biblScope unit="page" from="948" to="958" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">New insights, current concepts in the pathophysiology of inflammatory myopathies</title>
		<author>
			<persName><forename type="first">J</forename><surname>Mendell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Adv Immunother</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="12" to="16" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Combined influence of amyloidbeta precursor protein gene transfer and cholesterol excess on cultured human muscle fibers</title>
		<author>
			<persName><forename type="first">J</forename><surname>Mcferrin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Leclerc</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page">A489</biblScope>
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Alpha4-beta1 Integrin Acts as a Cell Receptor for Murine Polyomavirus at the Postattachment Level</title>
		<author>
			<persName><forename type="first">M</forename><surname>Caruso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Belloni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Sthandier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Amati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Garcia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Virol</title>
		<imprint>
			<biblScope unit="volume">77</biblScope>
			<biblScope unit="page" from="3913" to="3921" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Oral simvastatin treatment in relapsing-remitting multiple sclerosis</title>
		<author>
			<persName><forename type="first">T</forename><surname>Vollmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Key</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Durkalski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Tyor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Corboy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">363</biblScope>
			<biblScope unit="page" from="1607" to="1608" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Trial of atorvastatin in Rheumatoid Arthritis (TARA): doubleblind, randomized placebo-controlled trial</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Mccarey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">366</biblScope>
			<biblScope unit="page" from="2015" to="2021" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin</title>
		<author>
			<persName><forename type="first">R</forename><surname>Stanislaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Pahan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Singh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurosci Lett</title>
		<imprint>
			<biblScope unit="volume">269</biblScope>
			<biblScope unit="page" from="71" to="74" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin</title>
		<author>
			<persName><forename type="first">O</forename><surname>Aktas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Exp Med</title>
		<imprint>
			<biblScope unit="volume">197</biblScope>
			<biblScope unit="page" from="725" to="733" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Lovastatin inhibits brain endothelial Rho-mediated lymphocyte migation and attenuates experimental autoimmune encephalomyelitis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Greenwood</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">FASEB J</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="905" to="907" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
